title: FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.
abstract: This study examines the clinical impact of PTEN genomic deletions using fluorescence in situ hybridisation (FISH) analysis of 107 prostate cancers, with follow-up information covering a period of up to 10 years. Tissue microarray analysis using interphase FISH indicated that hemizygous PTEN losses were present in 42/107 (39%) of prostatic adenocarcinomas, with a homozygous PTEN deletion observed in 5/107 (5%) tumours. FISH analysis using closely linked probes centromeric and telomeric to the PTEN indicated that subband microdeletions accounted for approximately 70% genomic losses. Kaplan-Meier survival analysis of PTEN genomic losses (hemizygous and homozygous deletion vs not deleted) identified subgroups with different prognosis based on their time to biochemical relapse after surgery, and demonstrated significant association between PTEN deletion and an earlier onset of disease recurrence (as determined by prostate-specific antigen levels). Homozygous PTEN deletion was associated with a much earlier onset of biochemical recurrence (P=0.002). Furthermore, PTEN loss at the time of prostatectomy correlated with clinical parameters of more advanced disease, such as extraprostatic extension and seminal vesicle invasion. Collectively, our data indicates that haploinsufficiency or PTEN genomic loss is an indicator of more advanced disease at surgery, and is predictive of a shorter time to biochemical recurrence of disease.
authors: Division of Applied Molecular Oncology, Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada.
authors: M
authors: M
authors: Yoshimoto
authors: I W
authors: IW
authors: Cunha
authors: R A
authors: RA
authors: Coudry
authors: F P
authors: FP
authors: Fonseca
authors: C H
authors: CH
authors: Torres
authors: F A
authors: FA
authors: Soares
authors: J A
authors: JA
authors: Squire
mesh_terms: D000368:Aged; D002872:Chromosome Deletion; D002879:Chromosomes, Human, Pair 10; D017353:Gene Deletion; D006720:Homozygote; D006801:Humans; D017404:In Situ Hybridization, Fluorescence / Q000379:methods*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D051059:PTEN Phosphohydrolase / Q000235:genetics*; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000235:genetics / Q000473:pathology*
chemical_list: D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human
references: Cell. 2007 Jan 12;128(1):25-8
references: 17218252
references: Genomics. 1997 Nov 15;46(1):70-7
references: 9403060
references: Genes Chromosomes Cancer. 2004 Mar;39(3):249-56
references: 14732926
references: J Mol Diagn. 2006 May;8(2):141-51
references: 16645199
references: Prostate. 2006 Jun 15;66(9):895-902
references: 16496415
references: Lancet. 2003 Mar 15;361(9361):955-64
references: 12648986
references: Anal Quant Cytol Histol. 1998 Oct;20(5):373-80
references: 9801755
references: Cancer Res. 2006 Apr 1;66(7):3396-400
references: 16585160
references: Oncogene. 2002 Mar 27;21(13):1955-62
references: 11960368
references: Genes Chromosomes Cancer. 2006 Nov;45(11):1018-32
references: 16897747
references: Genes Chromosomes Cancer. 2006 Feb;45(2):154-63
references: 16235241
references: Nat Med. 2004 Jun;10(6):594-601
references: 15156201
references: Nat Genet. 1995 Apr;9(4):401-6
references: 7795646
references: Eur J Biochem. 1999 Aug;263(3):605-11
references: 10469123
references: Br J Cancer. 2001 Jan;84(2):202-8
references: 11161378
references: CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30
references: 16514137
references: J Biol Chem. 2000 Aug 11;275(32):24500-5
references: 10827191
references: Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5246-50
references: 9560261
references: Mod Pathol. 2005 Sep;18(9):1258-63
references: 15832192
references: Br J Cancer. 1999 May;80(3-4):519-25
references: 10408862
references: Genes Chromosomes Cancer. 2000 Oct;29(2):117-29
references: 10959091
references: Science. 1998 Nov 13;282(5392):1318-21
references: 9812896
references: Cell. 1997 Oct 17;91(2):231-41
references: 9346240
references: Neoplasia. 2006 Oct;8(10):826-32
references: 17032499
references: Cancer Genet Cytogenet. 2006 Sep;169(2):128-37
references: 16938570
references: Cancer Res. 2006 Sep 1;66(17):8337-41
references: 16951139
references: Hum Mol Genet. 2003 Oct 15;12 Spec No 2:R239-48
references: 12928488
references: Neoplasia. 2006 Jun;8(6):465-9
references: 16820092
references: BMC Genomics. 2006;7:65
references: 16573809
references: Ann Med. 2001 Mar;33(2):130-41
references: 11327116
references: Cancer Genet Cytogenet. 2000 Oct 1;122(1):43-8
references: 11104032
references: Int J Cancer. 2007 Mar 15;120(6):1284-92
references: 17163422
references: Rev Urol. 2001;3 Suppl 2:S11-9
references: 16985995
references: J Clin Invest. 2004 Mar;113(6):913-23
references: 15067324
references: Urol Oncol. 2004 Jul-Aug;22(4):307-12
references: 15283888
references: Cancer Genet Cytogenet. 2002 Aug;137(1):59-63
references: 12377415
references: Mol Cancer. 2006;5:33
references: 16952311
references: Cancer Res. 1999 Sep 1;59(17):4291-6
references: 10485474
references: Genes Chromosomes Cancer. 2006 Jul;45(7):717-9
references: 16575875
references: Prostate. 2005 Jan 1;62(1):61-8
references: 15389810
references: Cancer Res. 2006 Sep 1;66(17):8347-51
references: 16951141
references: Cell. 1999 Mar 19;96(6):857-68
references: 10102273
references: Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11563-8
references: 11553783
references: J Pathol. 2006 Apr;208(5):699-707
references: 16402365
references: Science. 2005 Oct 28;310(5748):644-8
references: 16254181
references: Pathol Int. 2004 Jun;54(6):413-9
references: 15144400
references: Neoplasia. 2004 May-Jun;6(3):240-7
references: 15153336
references: Cancer Biol Ther. 2006 Mar;5(3):254-5
references: 16575200